BASF to spend €200m to up ibuprofen capacity in Europe and US

By Gareth Macdonald

- Last updated on GMT


Related tags Pharmaceutical drug Pharmacology

BASF has said it will build an ibuprofen plant in Ludwigshafen, Germany and increase production capacity for the API at a facility in Bishop, Texas in the US.

The German chemicals firm described the new facility – which is due to be operational in 2021 – as the “first world-scale ibuprofen plant in Europe​.”

BASF said the Texas plant expansion is designed to "fill current supply gaps for ibuprofen in the market​" adding that the "expansion will come onstream in early 2018​."

The company said it will invest approximately €200m ($227m) in both projects.

Ibuprofen is one of only a handful of active pharmaceutical ingredients (APIs) that BASF still makes. 

The firm sold most of its drug ingredient portfolio and several manufacturing facilities to Swiss firm Siegfried Holdings in 2015​. The only APIs that BASF retained, in addition to ibuprofen, were its portfolio of omega-3 based actives. 

BASF declined to disclose its current ibuprofen production capacity when contacted by in-Pharmatechnologist, but did say it "is a market leader for Ibuprofen in regards to sales and total capacity​."

The firm also told us "the investment will create in Ludwigshafen additional jobs that number in the range of the middle double digits​."

API business

BASF's remaining API business had a mixed 2016.

In July​ last year the firm reported that lower demand for drug actives had seen sales volumes dip in its nutrition & health division.

However, in its full year report​ BASF said the division had seen sales volumes increase, explaining that "demand grew, especially in the pharmaceuticals and animal nutrition businesses​."

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...